Sagimet Biosciences Inc (SGMT)
4.62
-0.13
(-2.74%)
USD |
NASDAQ |
May 17, 16:00
4.62
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Cash from Investing (Quarterly): 3.00M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.00M |
| December 31, 2023 | -19.62M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 12.80M |
| March 31, 2023 | 19.40M |
| Date | Value |
|---|---|
| December 31, 2022 | 5.436M |
| September 30, 2022 | 4.00M |
| June 30, 2022 | -41.45M |
| March 31, 2022 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-41.45M
Minimum
Jun 2022
19.40M
Maximum
Mar 2023
-1.826M
Average
3.00M
Median
Mar 2024
Cash from Investing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 98.05M |
| Viking Therapeutics Inc | -459.79M |
| 89bio Inc | -79.90M |
| Arrowhead Pharmaceuticals Inc | -268.94M |
| Akero Therapeutics Inc | 57.85M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.208M |
| Cash from Financing (Quarterly) | 104.85M |
| Free Cash Flow | -22.89M |
| Free Cash Flow Per Share (Quarterly) | -0.2138 |
| Free Cash Flow Yield | -21.47% |